Peripheral Leucopenia as a Predictor of Virological Response in Adult Egyptian Patients with HCV Treated with Pegylated Interferon and Ribavirin
Rasha Fathi Ali;
Abstract
Summary
T
heaimofourstudyistoevaluatetheusefulnessofleucopeniaandneutropniaaspredictorsofsustainedvirologicalresponsetotreatmentofchronichepatitisCwithPEG-IFNandRibavirinfor48weeks.
Thestudyincluded200patientswithchronichepatitisCinfectionattendingtheinterferonclinicofmadinetnasrpolicehospital,Al-AgouzapolicehospitalandAl-QahiraAl-Gadidahospital.
Allpatientsweresubjectedto:
• Carefulhistorytaking.
• Fullclinicalexaminationtodetectmanifestationsofchronicliverdisease,itscomplicationsorotherassociateddiseases.
• Laboratoryinvestigations:
1- Completebloodpicture.
2- LiverfunctiontestsasserumAST,ALT,serumbilirubin,serumalbumin,INR.
3- Renalfunctiontests:serumcreatinineandbloodurea.
4- Fastingandpostprandialbloodglucoselevel.
5- Preparatoryinvestigationsbeforeinterferontherapytoexcludeautoimmunecausesofchronicliverdisease(ANA,ASMAandAMA)orthyroiddisease(freeT3,freeT4andTSH).
6- Abdominalultrasoundandliverbiopsytodetectthestageoffibrosis.
Inthestudiedgroup:
1- Wefoundnostatisticallydifferencebetweenanemia,leucopenia,neutropeniaandthrombocytopeniaatweeks12,24and48oftreatmentandcasesage.
2- Thereisnostatisticallydifferencebetweenmaleandfemale patientsinregardtooccurrenceofhematologicaltoxicityonweeks12,24and48weeksoftreatment.
3- Itwasfoundthatthereisnosignificantdifferencebetweencaseswithpretreatment HCVPCR≥720000IU/mlor<720000IU/mlandoccurrenceofhematologicaltoxicitiesonweeks12,24and48oftreatment.
4- Itwasfoundthatoccurrenceofanemiaonweeks12,24and48weeksoftreatmentissignificantlyassociatedwithSVR.
5- Itwasfoundthatthereisnostatisticaldifferencebetweenpatientswithandwithoutleucopeniaatweeks12,24and48oftreatmentandachievingSVR.
6- Itwasfoundthatthereisnostatisticaldifferencebetweenpatientswithandwithoutneutropeniaatweeks12,24and48oftreatmentandachievingSVR.
7- Itwasfoundthatthereisnostatisticaldifferencebetweenpatientswithandwithoutthrombocytopeniaatweeks12,24and48oftreatmentandachievingSVR.
8- IndependentfactorsthataresignificantlyassociatedwithhigherSVRare:femalesex (p=0.016),pretreatmentHCV PCR<720000 IU/ml (p=0.001),occurrenceofanemia,neutropenia,orthrombo-cytopeniaatweek12oftreatment (p=0.0001, 0.036 and 0.038 respectively),occurrenceofleucopeniaatweek24oftreatment (p=0.003)andoccurrenceofanemiaatweek48oftreatment (p=0.039).
T
heaimofourstudyistoevaluatetheusefulnessofleucopeniaandneutropniaaspredictorsofsustainedvirologicalresponsetotreatmentofchronichepatitisCwithPEG-IFNandRibavirinfor48weeks.
Thestudyincluded200patientswithchronichepatitisCinfectionattendingtheinterferonclinicofmadinetnasrpolicehospital,Al-AgouzapolicehospitalandAl-QahiraAl-Gadidahospital.
Allpatientsweresubjectedto:
• Carefulhistorytaking.
• Fullclinicalexaminationtodetectmanifestationsofchronicliverdisease,itscomplicationsorotherassociateddiseases.
• Laboratoryinvestigations:
1- Completebloodpicture.
2- LiverfunctiontestsasserumAST,ALT,serumbilirubin,serumalbumin,INR.
3- Renalfunctiontests:serumcreatinineandbloodurea.
4- Fastingandpostprandialbloodglucoselevel.
5- Preparatoryinvestigationsbeforeinterferontherapytoexcludeautoimmunecausesofchronicliverdisease(ANA,ASMAandAMA)orthyroiddisease(freeT3,freeT4andTSH).
6- Abdominalultrasoundandliverbiopsytodetectthestageoffibrosis.
Inthestudiedgroup:
1- Wefoundnostatisticallydifferencebetweenanemia,leucopenia,neutropeniaandthrombocytopeniaatweeks12,24and48oftreatmentandcasesage.
2- Thereisnostatisticallydifferencebetweenmaleandfemale patientsinregardtooccurrenceofhematologicaltoxicityonweeks12,24and48weeksoftreatment.
3- Itwasfoundthatthereisnosignificantdifferencebetweencaseswithpretreatment HCVPCR≥720000IU/mlor<720000IU/mlandoccurrenceofhematologicaltoxicitiesonweeks12,24and48oftreatment.
4- Itwasfoundthatoccurrenceofanemiaonweeks12,24and48weeksoftreatmentissignificantlyassociatedwithSVR.
5- Itwasfoundthatthereisnostatisticaldifferencebetweenpatientswithandwithoutleucopeniaatweeks12,24and48oftreatmentandachievingSVR.
6- Itwasfoundthatthereisnostatisticaldifferencebetweenpatientswithandwithoutneutropeniaatweeks12,24and48oftreatmentandachievingSVR.
7- Itwasfoundthatthereisnostatisticaldifferencebetweenpatientswithandwithoutthrombocytopeniaatweeks12,24and48oftreatmentandachievingSVR.
8- IndependentfactorsthataresignificantlyassociatedwithhigherSVRare:femalesex (p=0.016),pretreatmentHCV PCR<720000 IU/ml (p=0.001),occurrenceofanemia,neutropenia,orthrombo-cytopeniaatweek12oftreatment (p=0.0001, 0.036 and 0.038 respectively),occurrenceofleucopeniaatweek24oftreatment (p=0.003)andoccurrenceofanemiaatweek48oftreatment (p=0.039).
Other data
| Title | Peripheral Leucopenia as a Predictor of Virological Response in Adult Egyptian Patients with HCV Treated with Pegylated Interferon and Ribavirin | Other Titles | تقييم العلاقة بين نقص خلايا الدم المناعية والرد الفعل الفيروسي لدي مرضى فيروس سي المصريين البالغين تحت العلاج بالانترفيرون طويل المدى والريبافيرين | Authors | Rasha Fathi Ali | Issue Date | 2015 |
Recommend this item
Similar Items from Core Recommender Database
Items in Ain Shams Scholar are protected by copyright, with all rights reserved, unless otherwise indicated.